AR097732A1 - Composiciones que comprenden poblaciones heterogéneas de proteínas recombinantes humanas de factor xa de coagulación - Google Patents

Composiciones que comprenden poblaciones heterogéneas de proteínas recombinantes humanas de factor xa de coagulación

Info

Publication number
AR097732A1
AR097732A1 ARP140103512A ARP140103512A AR097732A1 AR 097732 A1 AR097732 A1 AR 097732A1 AR P140103512 A ARP140103512 A AR P140103512A AR P140103512 A ARP140103512 A AR P140103512A AR 097732 A1 AR097732 A1 AR 097732A1
Authority
AR
Argentina
Prior art keywords
compositions
factor
heterogenic
populations
coagulation
Prior art date
Application number
ARP140103512A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR097732A1 publication Critical patent/AR097732A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6432Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Water Supply & Treatment (AREA)
  • Toxicology (AREA)
ARP140103512A 2013-09-24 2014-09-23 Composiciones que comprenden poblaciones heterogéneas de proteínas recombinantes humanas de factor xa de coagulación AR097732A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361881834P 2013-09-24 2013-09-24

Publications (1)

Publication Number Publication Date
AR097732A1 true AR097732A1 (es) 2016-04-13

Family

ID=51844797

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103512A AR097732A1 (es) 2013-09-24 2014-09-23 Composiciones que comprenden poblaciones heterogéneas de proteínas recombinantes humanas de factor xa de coagulación

Country Status (19)

Country Link
US (3) US9757434B2 (cg-RX-API-DMAC7.html)
EP (1) EP3049434A1 (cg-RX-API-DMAC7.html)
JP (1) JP6429885B2 (cg-RX-API-DMAC7.html)
KR (1) KR101988705B1 (cg-RX-API-DMAC7.html)
CN (2) CN105579468A (cg-RX-API-DMAC7.html)
AR (1) AR097732A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014326257B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016005899A8 (cg-RX-API-DMAC7.html)
CA (1) CA2924981C (cg-RX-API-DMAC7.html)
HK (1) HK1218760A1 (cg-RX-API-DMAC7.html)
IL (2) IL244258A0 (cg-RX-API-DMAC7.html)
MX (1) MX373466B (cg-RX-API-DMAC7.html)
MY (1) MY173548A (cg-RX-API-DMAC7.html)
PE (1) PE20160877A1 (cg-RX-API-DMAC7.html)
RU (1) RU2648144C2 (cg-RX-API-DMAC7.html)
SA (1) SA516370751B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201601221XA (cg-RX-API-DMAC7.html)
TW (1) TWI631134B (cg-RX-API-DMAC7.html)
WO (1) WO2015044836A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1215196A1 (zh) 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法
AU2014326257B2 (en) 2013-09-24 2017-08-10 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins
PE20190661A1 (es) * 2016-06-17 2019-05-08 Portola Pharm Inc Preparacion de derivados del factor xa
EP3722418A1 (en) * 2019-04-08 2020-10-14 AB Enzymes Oy Solution stable enzyme composition

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
JP2008509688A (ja) * 2004-08-17 2008-04-03 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 改変ビタミンk依存性ポリペプチド
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX336958B (es) 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
DK2915564T3 (da) * 2007-09-28 2021-02-08 Alexion Pharma Inc Antidoter mod faktor XA-inhibitorer og fremgangsmåder til anvendelse deraf
AU2009264282B2 (en) 2008-06-24 2013-04-18 Octapharma Ag A process of purifying coagulation factor VIII
JP5709316B2 (ja) 2008-11-14 2015-04-30 ポートラ ファーマシューティカルズ, インコーポレイテッド 第Xa因子阻害剤のための解毒剤および血液凝固剤と組み合わせて該解毒剤を使用する方法
US8436144B2 (en) 2008-12-19 2013-05-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders
EP2453910B1 (en) * 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding
EA201291482A1 (ru) * 2010-07-09 2013-10-30 Байоджен Айдек Хемофилия Инк. Химерные факторы коагуляции
FR2972114B1 (fr) 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
AU2012315516B2 (en) 2011-09-30 2017-05-04 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
MX365612B (es) 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.
HK1215196A1 (zh) 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法
AU2014326257B2 (en) 2013-09-24 2017-08-10 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins
CA2928762A1 (en) 2013-11-01 2015-05-07 The Children's Hospital Of Philadelphia Compositions and methods for increasing the half-life of factor xa
MX375355B (es) 2014-01-24 2025-03-04 Pfizer Una variante del factor xa para usarse en el tratamiento de la hemorragia cerebral.

Also Published As

Publication number Publication date
BR112016005899A8 (pt) 2018-02-06
KR20160044034A (ko) 2016-04-22
CN105579468A (zh) 2016-05-11
US20150182604A1 (en) 2015-07-02
TWI631134B (zh) 2018-08-01
AU2014326257A1 (en) 2016-03-10
IL244258A0 (en) 2016-04-21
BR112016005899A2 (pt) 2017-09-26
TW201524996A (zh) 2015-07-01
JP6429885B2 (ja) 2018-11-28
AU2014326257B2 (en) 2017-08-10
KR101988705B1 (ko) 2019-06-12
EP3049434A1 (en) 2016-08-03
CA2924981A1 (en) 2015-04-02
WO2015044836A1 (en) 2015-04-02
US20170333535A1 (en) 2017-11-23
MX2016003871A (es) 2016-08-04
RU2648144C2 (ru) 2018-03-22
IL279396A (en) 2021-01-31
PE20160877A1 (es) 2016-09-11
MX373466B (es) 2020-05-25
CA2924981C (en) 2020-03-31
MY173548A (en) 2020-02-04
RU2016108608A (ru) 2017-10-26
CN112195169A (zh) 2021-01-08
SG11201601221XA (en) 2016-04-28
US20210106658A1 (en) 2021-04-15
HK1218760A1 (zh) 2017-03-10
JP2016535071A (ja) 2016-11-10
US9757434B2 (en) 2017-09-12
US10660946B2 (en) 2020-05-26
SA516370751B1 (ar) 2018-04-05

Similar Documents

Publication Publication Date Title
CY1126072T1 (el) Περιοχες gla ως θεραπευτικοι παραγοντες
DK3377637T3 (da) Sammensætninger til anvendelse i fremgangsmåder til behandling af sår, lidelser og sygdomme i huden
BR112017016952A2 (pt) terapia de combinação com fatores de coagulação e anticorpos multiespecíficos
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
EA201690556A1 (ru) Способы и фармацевтические композиции для лечения вызванных вирусом гепатита в инфекций
MX2020013362A (es) Metodos para la liberacion de cromolina.
SV2018005714A (es) Composiciones y metodos para disminuir la expresion de tau
IL257986B (en) Expression of recombinant proteins in trichoplusia ni pupae
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
AR097732A1 (es) Composiciones que comprenden poblaciones heterogéneas de proteínas recombinantes humanas de factor xa de coagulación
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
EA201690855A1 (ru) Эндоглиновые пептиды для лечения фиброзных заболеваний
EP3634460A4 (en) S-NITROSOGLUTATHIOMA (GSNO) AND REDUCTASE INHIBITORS FOR USE IN THERAPY
CY1121000T1 (el) Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων
HUE054330T2 (hu) Graft versus host betegség kezelése transzplantációs betegekben
MX2019005693A (es) Factor viii direccionado a los globulos rojos y metodo para su uso.
MX387579B (es) Polipéptidos del factor vii de acción corta.
MX2015014265A (es) Combinacion sinergica de alanina-glutamina, acido hialuronico y un extracto de avena y su uso en una composicion destinada para la curacion de heridas y reparacion de lesiones de la piel.
MX2015011418A (es) Tratamiento de enfermedades con nanofibras de poli-n-acetilglucosamina.
HRP20181352T1 (hr) Postupci i reagensi za održavanje vijabilnosti stanica raka u kirurški odstranjenom tkivu
EP3542808C0 (en) THERAPEUTIC VIRAL MICROPARTICLES TO PROMOTE STENT BIOFUNCTIONALITY AND HEALING IN VERTEBRATE INDIVIDUALS
EA201692161A1 (ru) Прогемостатические белки для лечения кровотечений
PH12014501044A1 (en) Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells
PH12016500509B1 (en) Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
MX385558B (es) Péptidos y métodos de uso.

Legal Events

Date Code Title Description
FB Suspension of granting procedure